AngioDynamics, Inc. (ANGO) Stock

About AngioDynamics, Inc.

AngioDynamics, Inc. is led by CEO James C. Clemmer, employs 748 people, headquartered in US, publicly traded since 2004.

AngioDynamics, Inc. (ANGO) stock trades at $12.37 with a market capitalization of $520.00M. The stock is valued at a negative price-to-earnings (P/E) ratio of -17.17, reflecting a net loss over the last twelve months, price-to-book of 3.67, price-to-sales of 1.95. Over the past 52 weeks the stock has ranged between $9.39 and $16.29, and currently trades 24.1% below its 52-week high.

On profitability, AngioDynamics, Inc. generates a return on equity (ROE) of -21.01% (negative, reflecting a net loss), return on capital employed of -20.75%, an operating margin of -13.70%, a net profit margin of -11.48%.

AngioDynamics, Inc. by the numbers, 2017–2026

Between 2017 and 2026 AngioDynamics, Inc. reported revenue of $350.0M rising to $320.0M, a change of -8.6% across 10 years. Compounded, revenue has grown 1.9% a year over five years, -1.9% over three, 9.6% over the last twelve months. Net profit fell to $-37.0M.

Operating margin went from -3.2% in 2017 to -12.5% in 2026, a fall of 9.3 percentage points. The most recent net margin is -11.48%. On a trailing twelve-month basis to Jun '26, revenue is $320.0M and net profit $-36.0M.

Borrowings fell from $106.0M to $0, cash from operations was $3.0M in the latest year, positive in 5 of the last 10.

Return on equity has averaged -29.9% over five years, and was -21.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

AngioDynamics, Inc. (ANGO) — frequently asked questions